Ocular Therapeutix will participate in Clinical Trials at the Summit 2026, presenting its investigational product AXPAXLI for retinal diseases.
Quiver AI Summary
Ocular Therapeutix, Inc., a biopharmaceutical company focused on retinal treatments, announced its participation in the Clinical Trials at the Summit 2026 event in Las Vegas, scheduled for June 12-13, 2026. The company will feature various presentations, including a fireside chat and presentations on its investigational product candidate AXPAXLI, which is entering Phase 3 trials for conditions like wet age-related macular degeneration and non-proliferative diabetic retinopathy. Key team members, including Dr. Peter K. Kaiser and Dr. Mark R. Barakat, will discuss the scientific and efficacy outcomes of the therapy, as well as the safety profile and ongoing updates from their HELIOS program. Ocular also highlights its other products, including DEXTENZA, an FDA-approved treatment, and OTX-TIC, currently being evaluated further.
Potential Positives
- Ocular Therapeutix is showcasing its commitment to innovation in retinal treatments by participating in the Clinical Trials at the Summit 2026, highlighting its investigational product AXPAXLI™.
- The company is presenting multiple significant updates on the OTX-TKI program, which is currently in Phase 3 trials for wet AMD and diabetic retinal disease, indicating strong progress in its pipeline.
- Ocular's leadership, including the Chief Development Officer, is engaging in discussions and panels about innovations in bringing novel treatments to market, which enhances the company's visibility and credibility in the industry.
- The release emphasizes the proprietary ELUTYX™ technology, showcasing Ocular's unique approach to treatment and differentiation from competitors in the biopharmaceutical space.
Potential Negatives
- Press release does not provide specific data or results from the ongoing Phase 3 trials for OTX-TKI, leaving stakeholders without critical performance insights.
- Participation in the Clinical Trials at the Summit does not guarantee successful outcomes or advancements in regulatory approval, which may affect investor confidence.
FAQ
What is Ocular Therapeutix's participation in Clinical Trials at the Summit 2026?
Ocular Therapeutix will participate in the summit with presentations focusing on their investigational product OTX-TKI and associated clinical trials.
When will Ocular Therapeutix present at the summit?
The presentations are scheduled for June 13, 2026, with various topics on clinical trials related to retinal diseases.
Who are the key speakers from Ocular Therapeutix at the event?
Key speakers include Peter K. Kaiser, MD, and Mark R. Barakat, MD, among others involved in OTX-TKI presentations.
What is the focus of the OTX-TKI product presentation?
The focus will be on the efficacy and safety outcomes of OTX-TKI for wet age-related macular degeneration and diabetic retinal disease.
How does Ocular Therapeutix contribute to retinal disease treatment?
Ocular Therapeutix develops advanced formulations like OTX-TKI and DEXTENZA to improve treatment for retinal diseases and related conditions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 16 times in the past 6 months. Of those trades, 1 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 3 sales selling 166,094 shares for an estimated $1,468,476.
- RICHARD L MD LINDSTROM purchased 60,229 shares for an estimated $461,354
- DONALD NOTMAN (Chief Operating Officer) has made 0 purchases and 3 sales selling 22,936 shares for an estimated $204,869.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 3 sales selling 13,965 shares for an estimated $123,346.
- NADIA WAHEED (Chief Medical Officer) has made 0 purchases and 2 sales selling 11,373 shares for an estimated $98,248.
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 2 sales selling 6,075 shares for an estimated $50,059.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 2 sales selling 5,777 shares for an estimated $47,596.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OCUL Hedge Fund Activity
We have seen 174 institutional investors add shares of $OCUL stock to their portfolio, and 120 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 11,615,868 shares (+143.9%) to their portfolio in Q1 2026, for an estimated $98,386,401
- VR ADVISER, LLC removed 5,845,915 shares (-44.4%) from their portfolio in Q4 2025, for an estimated $70,969,408
- PRICE T ROWE ASSOCIATES INC /MD/ added 5,725,625 shares (+3338.1%) to their portfolio in Q1 2026, for an estimated $48,496,043
- POINT72 ASSET MANAGEMENT, L.P. added 4,518,737 shares (+444.6%) to their portfolio in Q1 2026, for an estimated $38,273,702
- TCG CROSSOVER MANAGEMENT, LLC removed 4,092,479 shares (-71.3%) from their portfolio in Q1 2026, for an estimated $34,663,297
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,004,350 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,916,844
- MILLENNIUM MANAGEMENT LLC removed 3,173,875 shares (-98.9%) from their portfolio in Q1 2026, for an estimated $26,882,721
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OCUL Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Clear Street issued a "Buy" rating on 03/03/2026
- Chardan Capital issued a "Buy" rating on 02/18/2026
To track analyst ratings and price targets for $OCUL, check out Quiver Quantitative's $OCUL forecast page.
$OCUL Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 5 analysts offer price targets for $OCUL in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $30.0 on 05/06/2026
- Serge Belanger from Needham set a target price of $18.0 on 05/05/2026
- Yi Chen from HC Wainwright & Co. set a target price of $21.0 on 04/13/2026
- Bill Maughan from Clear Street set a target price of $28.0 on 03/03/2026
- Daniil Gataulin from Chardan Capital set a target price of $21.0 on 02/18/2026
Full Release
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
Clinical Trials at the Summit (CTS) 2026 Presentation Details :
-
Fireside Chat with Wiley Chambers, MD
Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer
-
Presentation Title: OTX-TKI: Overview of Science
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026,10:41 – 10:45 AM PT
Presenter: Peter K. Kaiser, MD, Chief Development Officer
-
Presentation Title: SOL-1 Phase 3 Superiority Trial: Efficacy Outcomes with OTX-TKI in Neovascular AMD
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026,10:53 – 10:57 AM PT
Presenter: Mark R. Barakat, MD
-
Presentation Title: Safety and Tolerability Profile of OTX-TKI in Neovascular AMD
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026, 10:57 – 11:01 AM PT
Presenter: Darius M. Moshfeghi, MD
-
Presentation Title: HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026, 11:05 – 11:09 AM PT
Presenter: Patricio G. Schlottmann, MD
-
Fireside Chat: From Global KOL to CEO: The Journey of Innovation, Leadership, and Patient Impact
Fireside Date/Time: Saturday, June 13, 2026, 11:22 – 11:42 AM PT
Fireside Moderator: Arshad M. Khanani, MD, MA, FASRS
Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO
-
Panel Title: From Innovation to Approval: Bringing Novel Treatments to Market
Panel Date/Time: Saturday, June 13, 2026, 1:43 – 2:03 PM PT
Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Exact presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA ® , an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
[email protected]
